Medtronic Stock Is Simply Too Cheap To Ignore


  • Medtronic is a global medical technology company specializing in various medical devices.
  • The company’s revenues are well distributed among different segments, with cardiovascular being the largest segment.
  • Medtronic expects further growth in its cardiovascular and neuroscience segments, driven by product launches and the adoption of integrated solutions.
  • The current EV/EBITDA multiple of just 12-13x and a growing dividend yield of over 4% provide a good starting point to enter a long position today.
Female engineer preparing operating theatre light in factory clean room

Monty Rakusen/DigitalVision via Getty Images

The Company

Medtronic (NYSE:MDT) is a major global medical technology company based in Minnesota. They specialize in various medical devices, including those for cardiac rhythm management, spinal and surgical navigation, diabetes and neurological treatments, vascular therapies, and cardiac surgery.


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MDT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Hold On! Can’t find the equity research you’ve been looking for?

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing! There is a free trial and a special discount of 10% for you. Join us today!

Leave a Reply

Your email address will not be published. Required fields are marked *